Michael Yellin - Concepedia

Author

Michael Yellin

Also Known As

M J Yellin, M Yellin, M. J. Yellin, M. Yellin, M.J. Yellin, MICHAEL J. YELLIN, MJ Yellin, Mark Albertini, Michael J Yellin, Michael J. Yellin

187

Publications

26.5K

Citations

H-Index

Concepts

All Affiliations

Columbia University Celldex Therapeutics (United States)Providence Portland Medical Center Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute

About

Michael Yellin is an author at Columbia University specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	38	4.6K
2	Cell Biology	11	11	1.4K
3	Health Sciences	3	3	119
4	Allergy	2	2	840
5	Cellular Therapies	1	1	102

Michael Yellin

Publications

26.1K

Citations

H-Index

Page 1

	Year	Citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma F. Stephen Hodi, Steven O’Day, David F. McDermott, New England Journal of Medicine	2010	14.9K
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial Michael Weller, Nicholas Butowski, David Tran, The Lancet Oncology Egfrviii-expressing GlioblastomaNeuro-oncologyAct IvGliomaInternational Phase 3	2017	1.1K
Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4 Peter Attia, Giao Q. Phan, Ajay V. Maker, Journal of Clinical Oncology	2005	1K
Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4 Kimberly E Beck, Joseph Blansfield, Khoi Q. Tran, Journal of Clinical Oncology	2006	831
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade Stephanie G. Downey, Jacob A. Klapper, Franz O. Smith, Clinical Cancer Research	2007	624
Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study Ajay V. Maker, Giao Q. Phan, Peter Attia, Annals of Surgical Oncology Tumor ImmunologyInterleukin 2AllergyAutoimmune DiseasePhase I/ii Study	2005	489
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma Jeffrey S. Weber, Steven O’Day, Walter J. Urba, Journal of Clinical Oncology	2008	460
Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma Kristin M. Sanderson, Ronald Scotland, Peter P. Lee, Journal of Clinical Oncology	2004	433
Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination Linda Hammerich, Thomas U. Marron, Ranjan Upadhyay, Nature Medicine VaccinationTumor ImmunologyCancer ImmunosurveillanceMedicineSitu Vaccination	2019	423
Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). Seth Lederman, Michael Yellin, Alexander Krichevsky, The Journal of Experimental Medicine Lymphocyte DevelopmentAdaptive Immune SystemT-regulatory CellImmunologyImmunologic Mechanism	1992	351

Page 1